Screener
CG Oncology CGON D&A
D&A at other companies
Other financials
Where this comes from
Reported directly by CG Oncology in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: CG Oncology’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 8:45 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336918
FAQ
- What is CG Oncology's D&A?
- CG Oncology (CGON) reported D&A of $850K in Q2 2026.
- How has CG Oncology's D&A changed year-over-year?
- CG Oncology's D&A increased by 444.9% year-over-year, from $156K to $850K.
- What is the long-term trend for CG Oncology's D&A?
- Over 2 years (2023 to 2025), CG Oncology's D&A has grown at a 822.0% compound annual growth rate (CAGR), from $17K to $1.45M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about CG Oncology's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude